609 related articles for article (PubMed ID: 18287210)
1. MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis.
Clark P; Rowland SE; Denis D; Mathieu MC; Stocco R; Poirier H; Burch J; Han Y; Audoly L; Therien AG; Xu D
J Pharmacol Exp Ther; 2008 May; 325(2):425-34. PubMed ID: 18287210
[TBL] [Abstract][Full Text] [Related]
2. Prostacyclin antagonism reduces pain and inflammation in rodent models of hyperalgesia and chronic arthritis.
Pulichino AM; Rowland S; Wu T; Clark P; Xu D; Mathieu MC; Riendeau D; Audoly LP
J Pharmacol Exp Ther; 2006 Dec; 319(3):1043-50. PubMed ID: 16973887
[TBL] [Abstract][Full Text] [Related]
3. Effect of prostanoid EP4 receptor antagonist, CJ-042,794, in rat models of pain and inflammation.
Murase A; Okumura T; Sakakibara A; Tonai-Kachi H; Nakao K; Takada J
Eur J Pharmacol; 2008 Feb; 580(1-2):116-21. PubMed ID: 18031725
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological and molecular characterization of the mechanisms involved in prostaglandin E2-induced mouse paw edema.
Claudino RF; Kassuya CA; Ferreira J; Calixto JB
J Pharmacol Exp Ther; 2006 Aug; 318(2):611-8. PubMed ID: 16644903
[TBL] [Abstract][Full Text] [Related]
5. MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation.
Xu D; Rowland SE; Clark P; Giroux A; Côté B; Guiral S; Salem M; Ducharme Y; Friesen RW; Méthot N; Mancini J; Audoly L; Riendeau D
J Pharmacol Exp Ther; 2008 Sep; 326(3):754-63. PubMed ID: 18524979
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of a selective COX-2 inhibitor MF-tricyclic, [3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone], in multiple preclinical species.
Rowland SE; Clark P; Gordon R; Mullen AK; Guay J; Dufresne L; Brideau C; Cote B; Ducharme Y; Mancini J; Chan CC; Audoly L; Xu D
Eur J Pharmacol; 2007 Apr; 560(2-3):216-24. PubMed ID: 17316604
[TBL] [Abstract][Full Text] [Related]
7. Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells.
Robertson FM; Simeone AM; Mazumdar A; Shah AH; McMurray JS; Ghosh S; Cristofanilli M
J Exp Ther Oncol; 2008; 7(4):299-312. PubMed ID: 19227010
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin E2 derived from cyclooxygenases 1 and 2 mediates intestinal epithelial ion transport stimulated by the activation of protease-activated receptor 2.
van der Merwe JQ; Ohland CL; Hirota CL; MacNaughton WK
J Pharmacol Exp Ther; 2009 May; 329(2):747-52. PubMed ID: 19190238
[TBL] [Abstract][Full Text] [Related]
9. Periodic, partial inhibition of IkappaB Kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis.
Gillooly KM; Pattoli MA; Taylor TL; Chen L; Cheng L; Gregor KR; Whitney GS; Susulic V; Watterson SH; Kempson J; Pitts WJ; Booth-Lute H; Yang G; Davies P; Kukral DW; Strnad J; McIntyre KW; Darienzo CJ; Salter-Cid L; Yang Z; Wang-Iverson DB; Burke JR
J Pharmacol Exp Ther; 2009 Nov; 331(2):349-60. PubMed ID: 19652024
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain.
Colucci J; Boyd M; Berthelette C; Chiasson JF; Wang Z; Ducharme Y; Friesen R; Wrona M; Levesque JF; Denis D; Mathieu MC; Stocco R; Therien AG; Clarke P; Rowland S; Xu D; Han Y
Bioorg Med Chem Lett; 2010 Jun; 20(12):3760-3. PubMed ID: 20471829
[TBL] [Abstract][Full Text] [Related]
11. The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis.
McCoy JM; Wicks JR; Audoly LP
J Clin Invest; 2002 Sep; 110(5):651-8. PubMed ID: 12208866
[TBL] [Abstract][Full Text] [Related]
12. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents.
Xu D; Kim Y; Postelnek J; Vu MD; Hu DQ; Liao C; Bradshaw M; Hsu J; Zhang J; Pashine A; Srinivasan D; Woods J; Levin A; O'Mahony A; Owens TD; Lou Y; Hill RJ; Narula S; DeMartino J; Fine JS
J Pharmacol Exp Ther; 2012 Apr; 341(1):90-103. PubMed ID: 22228807
[TBL] [Abstract][Full Text] [Related]
13. GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist.
Wilson RJ; Giblin GM; Roomans S; Rhodes SA; Cartwright KA; Shield VJ; Brown J; Wise A; Chowdhury J; Pritchard S; Coote J; Noel LS; Kenakin T; Burns-Kurtis CL; Morrison V; Gray DW; Giles H
Br J Pharmacol; 2006 Jun; 148(3):326-39. PubMed ID: 16604093
[TBL] [Abstract][Full Text] [Related]
14. Effect of 5-trifluoromethyl-4,5-dihydro-1H-pyrazoles on chronic inflammatory pain model in rats.
Sauzem PD; Sant'Anna Gda S; Machado P; Duarte MM; Ferreira J; Mello CF; Beck P; Bonacorso HG; Zanatta N; Martins MA; Rubin MA
Eur J Pharmacol; 2009 Aug; 616(1-3):91-100. PubMed ID: 19540223
[TBL] [Abstract][Full Text] [Related]
15. Antinociceptive pharmacology of N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[[(4-methoxy-2,6-dimethylphenyl) sulfonyl]methylamino]ethoxy]-N-methylacetamide, fumarate (LF22-0542), a novel nonpeptidic bradykinin B1 receptor antagonist.
Porreca F; Vanderah TW; Guo W; Barth M; Dodey P; Peyrou V; Luccarini JM; Junien JL; Pruneau D
J Pharmacol Exp Ther; 2006 Jul; 318(1):195-205. PubMed ID: 16565167
[TBL] [Abstract][Full Text] [Related]
16. Effect of Intra-articular 4-(S)-amino-5-(4-{4-[2,4-dichloro-3-(2,4-dimethyl-8-quinolyloxymethyl)phenylsulfonamido]-tetrahydro-2H-4-pyranylcarbonyl} piperazino)-5-oxopentyl](trimethyl)ammonium chloride hydrochloride (MEN16132), a kinin B2 receptor antagonist, on nociceptive response in monosodium iodoacetate-induced experimental osteoarthritis in rats.
Cialdai C; Giuliani S; Valenti C; Tramontana M; Maggi CA
J Pharmacol Exp Ther; 2009 Dec; 331(3):1025-32. PubMed ID: 19745108
[TBL] [Abstract][Full Text] [Related]
17. Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis.
Honda T; Segi-Nishida E; Miyachi Y; Narumiya S
J Exp Med; 2006 Feb; 203(2):325-35. PubMed ID: 16446378
[TBL] [Abstract][Full Text] [Related]
18. Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment.
Bar-Yehuda S; Rath-Wolfson L; Del Valle L; Ochaion A; Cohen S; Patoka R; Zozulya G; Barer F; Atar E; Piña-Oviedo S; Perez-Liz G; Castel D; Fishman P
Arthritis Rheum; 2009 Oct; 60(10):3061-71. PubMed ID: 19790055
[TBL] [Abstract][Full Text] [Related]
19. A novel antagonist of the prostaglandin E(2) EP(4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models.
Chen Q; Muramoto K; Masaaki N; Ding Y; Yang H; Mackey M; Li W; Inoue Y; Ackermann K; Shirota H; Matsumoto I; Spyvee M; Schiller S; Sumida T; Gusovsky F; Lamphier M
Br J Pharmacol; 2010 May; 160(2):292-310. PubMed ID: 20423341
[TBL] [Abstract][Full Text] [Related]
20. Valdecoxib.
Baker DE
Rev Gastroenterol Disord; 2002; 2(3):116-25. PubMed ID: 12227215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
